Novocure Study Meets Primary Endpoint; Treatment Shows Improvement Over Standard Therapies

Global oncology company, Novocure (NASDAQ: NVCR) has demonstrated statistically significant and clinically meaningful improvement in overall survival of patients over standard therapies alone in its Phase 3 LUNAR study.

The study is evaluating the safety and efficacy of Tumor Treating Fields (TTFields) together with standard therapies for stage 4 non-small cell lung cancer (NSCLC). 

Highlights

  • Novocure successfully demonstrated a statistically significant and clinically meaningful improvement in overall survival when patients were treated with:
    • TTFields and immune checkpoint inhibitors (ICI), as compared to those treated with immune checkpoint inhibitors alone;
    • And a positive trend in overall survival when patients were treated with TTFields and docetaxel versus docetaxel alone.
  • TTFields therapy was well tolerated by patients.
  • Novocure expects to file a Premarket Approval application with the U.S. Food and Drug Administration (FDA) in the second half of 2023

Approximately 46,000 patients receive second-line treatment for stage 4 NSCLC each year in the United States.

About the Author

Novocure Study Meets Primary Endpoint; Treatment Shows Improvement Over Standard Therapies

Editor Investors Prism